Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torbjörn Lundström

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Drugs in R&D|December 10, 2014
In Silico comparison between metoprolol succinate and bisoprolol on 24-hour systolic blood pressuresSven-Olof Jansson, Anders E Malm, Torbjörn Lundström
Veterinary Journal (London, England : 1997)|November 26, 2008
The prevalence of oral ulceration in Swedish horses when ridden with bit and bridle and when unriddenAnna Tell, Agneta Egenvall, Torbjörn Lundström, et al.
Acta Veterinaria Scandinavica|August 14, 2014
Bit-related lesions in Icelandic competition horsesSigríður Björnsdóttir, Rebecka Frey, Thorvaldur Kristjansson, et al.
Veterinary Immunology and Immunopathology|October 4, 2016
Secretory immunoglobulin A and immunoglobulin G in horse salivaAnna-Karin E Palm, Ove Wattle, Torbjörn Lundström, et al.
Acta Veterinaria Scandinavica|May 25, 2020
Equine saliva components during mastication, and in vivo pH changes in the oral biofilm of sound and carious tooth surfaces after sucrose exposureTorbjörn Lundström, Peter Lingström, Ove Wattle, et al.
Thrombosis and Haemostasis|November 5, 2005
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatranHenry Eriksson, Torbjörn Lundström, Karin Wåhlander, et al.
Thrombosis and Haemostasis|November 8, 2005
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III studySam Schulman, Torbjörn Lundström, Karin Wålander, et al.
The New England Journal of Medicine|October 31, 2003
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatranSam Schulman, Karin Wåhlander, Torbjörn Lundström, et al.
Clinical Pharmacology in Drug Development|June 10, 2017
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega-3-Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single-Blind, Randomized, Placebo-Controlled TrialYoshinori Noda, Catarina Nilsson, Hitoshi Shimada, et al.
Journal of Atherosclerosis and Thrombosis|March 28, 2017
Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover TrialHitoshi Shimada, Catarina Nilsson, Yoshinori Noda, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Drugs in R&D|December 10, 2014
In Silico comparison between metoprolol succinate and bisoprolol on 24-hour systolic blood pressuresSven-Olof Jansson, Anders E Malm, Torbjörn Lundström
Veterinary Journal (London, England : 1997)|November 26, 2008
The prevalence of oral ulceration in Swedish horses when ridden with bit and bridle and when unriddenAnna Tell, Agneta Egenvall, Torbjörn Lundström, et al.
Acta Veterinaria Scandinavica|August 14, 2014
Bit-related lesions in Icelandic competition horsesSigríður Björnsdóttir, Rebecka Frey, Thorvaldur Kristjansson, et al.
Veterinary Immunology and Immunopathology|October 4, 2016
Secretory immunoglobulin A and immunoglobulin G in horse salivaAnna-Karin E Palm, Ove Wattle, Torbjörn Lundström, et al.
Acta Veterinaria Scandinavica|May 25, 2020
Equine saliva components during mastication, and in vivo pH changes in the oral biofilm of sound and carious tooth surfaces after sucrose exposureTorbjörn Lundström, Peter Lingström, Ove Wattle, et al.
Thrombosis and Haemostasis|November 5, 2005
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatranHenry Eriksson, Torbjörn Lundström, Karin Wåhlander, et al.
Thrombosis and Haemostasis|November 8, 2005
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III studySam Schulman, Torbjörn Lundström, Karin Wålander, et al.
The New England Journal of Medicine|October 31, 2003
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatranSam Schulman, Karin Wåhlander, Torbjörn Lundström, et al.
Clinical Pharmacology in Drug Development|June 10, 2017
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega-3-Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single-Blind, Randomized, Placebo-Controlled TrialYoshinori Noda, Catarina Nilsson, Hitoshi Shimada, et al.
Journal of Atherosclerosis and Thrombosis|March 28, 2017
Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover TrialHitoshi Shimada, Catarina Nilsson, Yoshinori Noda, et al.
Pageof 2